- Home
- ARR vs IRON Comparison
ARR vs IRON Comparison
Compare ARR & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARR
- IRON
- Stock Information
- Founded
- ARR 2008
- IRON 2017
- Country
- ARR United States
- IRON United States
- Employees
- ARR N/A
- IRON N/A
- Industry
- ARR Real Estate Investment Trusts
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- ARR Real Estate
- IRON Health Care
- Exchange
- ARR Nasdaq
- IRON Nasdaq
- Market Cap
- ARR 1.8B
- IRON 2.1B
- IPO Year
- ARR N/A
- IRON N/A
- Fundamental
- Price
- ARR $15.63
- IRON $68.02
- Analyst Decision
- ARR Buy
- IRON Strong Buy
- Analyst Count
- ARR 4
- IRON 10
- Target Price
- ARR $15.50
- IRON $97.80
- AVG Volume (30 Days)
- ARR 3.5M
- IRON 340.9K
- Earning Date
- ARR 10-22-2025
- IRON 11-11-2025
- Dividend Yield
- ARR 18.47%
- IRON N/A
- EPS Growth
- ARR N/A
- IRON N/A
- EPS
- ARR N/A
- IRON N/A
- Revenue
- ARR $20,589,000.00
- IRON N/A
- Revenue This Year
- ARR $350.86
- IRON N/A
- Revenue Next Year
- ARR $54.46
- IRON N/A
- P/E Ratio
- ARR N/A
- IRON N/A
- Revenue Growth
- ARR N/A
- IRON N/A
- 52 Week Low
- ARR $13.18
- IRON $30.82
- 52 Week High
- ARR $20.39
- IRON $69.87
- Technical
- Relative Strength Index (RSI)
- ARR 61.38
- IRON 66.16
- Support Level
- ARR $14.00
- IRON $65.26
- Resistance Level
- ARR $15.73
- IRON $69.87
- Average True Range (ATR)
- ARR 0.31
- IRON 2.52
- MACD
- ARR 0.15
- IRON 0.54
- Stochastic Oscillator
- ARR 96.42
- IRON 80.55
About ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.